早期霍奇金淋巴瘤当代治疗的长期随访:德国霍奇金研究组HD7、HD8、HD10和HD11试验的更新分析
该更新分析纳入德国霍奇金研究组HD7、HD8、HD10和HD11四项随机试验中1993至2003年间治疗的4276例早期霍奇金淋巴瘤患者,长期随访证实联合模式治疗优于扩大野放疗,且降低治疗强度在有利型和不利型早期患者中均不劣于强化方案,但ABVD后20 Gy累及野放疗的PFS劣于30 Gy。
要点
- HD7中联合模式治疗15年PFS优于扩大野放疗(73%对52%,HR 0.5),OS无差异。
- HD10中2周期ABVD+20 Gy IF-RT不劣于4周期ABVD+30 Gy IF-RT,10年PFS均为87%。
- HD11中ABVD后20 Gy IF-RT的PFS劣于30 Gy(76%对84%,HR 1.5)。
核心结论
- 四项随机试验的长期随访数据在很大程度上支持当前早期霍奇金淋巴瘤的风险适应治疗策略。
- 仍需继续随访以评估当前所用治疗策略的长期安全性。
研究设计与样本
- 分析德国霍奇金研究组HD7和HD10(早期有利型霍奇金淋巴瘤)以及HD8和HD11(早期不利型霍奇金淋巴瘤)试验的更新随访数据。
- 共纳入1993年至2003年间治疗的4276例患者。
主要发现
- HD7(N=627;中位随访120个月):联合模式治疗15年无进展生存(PFS)为73%,扩大野放疗为52%(HR 0.5;95%CI 0.3至0.6;P<.001),总生存(OS)无差异。
- HD10(N=1190;中位随访98个月):2周期多柔比星、博来霉素、长春碱、达卡巴嗪(ABVD)联合20 Gy累及野放疗(IF-RT)对比4周期ABVD联合30 Gy IF-RT,10年PFS均为87%(HR 1.0;95%CI 0.6至1.5),OS均为94%(HR 0.9;95%CI 0.5至1.6),第二肿瘤无差异。
- HD8(N=1064;中位随访153个月):累及野放疗对比扩大野放疗,PFS非劣效(HR 1.0;95%CI 0.8至1.2)。
- HD11(N=1395;中位随访106个月):基线博来霉素、依托泊苷、多柔比星、环磷酰胺、长春新碱、丙卡巴肼和泼尼松(BEACOPPbaseline)对比ABVD未观察到优效性;BEACOPPbaseline后20 Gy IF-RT对比30 Gy,10年PFS均为84%(HR 1.0;95%CI 0.7至1.5),非劣效。
- HD11中ABVD治疗患者接受20 Gy对比30 Gy IF-RT,10年PFS为76%对84%(HR 1.5;95%CI 1.0至2.1),20 Gy组PFS劣于30 Gy组;两项试验中OS或第二肿瘤均无差异。
局限性
- 仍需继续随访以评估当前所用治疗策略的长期安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Combined-modality treatment is widely considered the standard of care in early-stage Hodgkin lymphoma (HL), and treatment intensity has been reduced over the last years. Long-term follow-up is important to judge both efficacy and safety of the different therapies used. Patients and Methods We analyzed updated follow-up data on 4,276 patients treated within the German Hodgkin Study Group trials HD7 and HD10 for early-stage favorable HL and HD8 and HD11 for early-stage unfavorable HL between 1993 and 2003. Results In HD7 (N = 627; median follow-up, 120 months), combined-modality treatment was superior to extended-field radiotherapy (RT), with 15-year progression-free survival (PFS) of 73% versus 52% (hazard ratio [HR], 0.5; 95% CI, 0.3 to 0.6; P < .001), without differences in overall survival (OS). In HD10 (N = 1,190; median follow-up, 98 months), noninferiority of two cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) plus 20 Gy involved-field (IF)-RT to more intensive four cycles of ABVD plus 30 Gy IF-RT was confirmed with 10-year PFS of 87% each (HR, 1.0; 95%, 0.6 to 1.5) and OS of 94% each (HR, 0.9; 95% CI, 0.5 to 1.6), respectively. In both trials, no differences in second neoplasias were observed. In HD8 (N = 1,064; median follow-up, 153 months), noninferiority of involved-field RT to extended-field RT regarding PFS was confirmed (HR, 1.0; 95% CI, 0.8 to 1.2). In HD11 (N = 1,395; median follow-up, 106 months), superiority of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at baseline over ABVD was not observed. After BEACOPPbaseline, 20 Gy IF-RT was noninferior to 30 Gy (10-year PFS, 84% v 84%; HR, 1.0; 95% CI, 0.7 to 1.5). In contrast, PFS was inferior in ABVD-treated patients receiving 20 Gy instead of 30 Gy IF-RT (10-year PFS, 76% v 84%; HR, 1.5; 95% CI, 1.0 to 2.1). No differences in OS or second neoplasias were observed in in both trials. Conclusion Long-term follow-up data of the four randomized trials largely support the current risk-adapted therapeutic strategies in early-stage HL. Nevertheless, continued follow-up is necessary to assess the long-term safety of currently applied therapeutic strategies.
引用
- Sasse S, Bröckelmann PJ, Goergen H, et al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol. 2017. PMID: 28418763. doi:10.1200/JCO.2016.70.9410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。